ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial ResultsGlobeNewsWire • 08/06/24
ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks Investment Research • 08/01/24
ARS Pharmaceuticals Inc Is Under Investigation By The Schall Law Firm And Impacted Investors Are Encouraged To Initiate DialoguesAccesswire • 07/19/24
The Schall Law Firm Is Investigating ARS Pharmaceuticals Inc And Urges Affected Investors To Start ConversationsAccesswire • 07/18/24
ARS Pharmaceuticals Inc Is Under Examination By The Schall Law Firm, Impacted Investors Are Encouraged To Initiate DialoguesAccesswire • 07/17/24
The Schall Law Firm Urges Affected Investors To Start Conversation, ARS Pharmaceuticals Inc Is Under ScrutinyAccesswire • 07/16/24
ARS Pharmaceuticals Inc Under Investigation By The Schall Law Firm Encouraging Impacted Investors To Initiate DialogueAccesswire • 07/15/24
The Schall Law Firm Begins Probe Into ARS Pharmaceuticals Inc And Urges Affected Investors To Start ConversationAccesswire • 07/13/24
Investigation Into ARS Pharmaceuticals Inc Initiated By The Schall Law Firm Encouraging Impacted Investors To Begin DialogueAccesswire • 07/12/24
ARS Pharmaceuticals Inc Under Investigation By The Schall Law Firm Urging Affected Investors To Initiate ConversationAccesswire • 07/11/24
The Schall Law Firm Initiates Inquiry Into ARS Pharmaceuticals Inc And Encourages Impacted Investors To Start DialogueAccesswire • 07/10/24
The Schall Law Firm Starts Investigation Into ARS Pharmaceuticals Inc And Urges Affected Investors To Begin InteractionAccesswire • 07/09/24
The Schall Law Firm Initiates Probe Into ARS Pharmaceuticals Inc And Encourages Impacted Investors To Start InteractionAccesswire • 07/08/24
The Schall Law Firm Starts Scrutiny Of Allegations Against ARS Pharmaceuticals Inc And Promotes Investors With Losses To Take PartAccesswire • 07/07/24
Investigation Into ARS Pharmaceuticals Inc Is Launched By The Schall Law Firm And It Motivates Affected Investors To EngageAccesswire • 07/06/24
The Schall Law Firm Initiates Examination Into Accusations Against ARS Pharmaceuticals Inc And Encourages Impacted Investors To ParticipateAccesswire • 07/05/24
The Schall Law Firm Commences Inquiry Into Allegations Against ARS Pharmaceuticals Inc And Urges Affected Investors To Get InvolvedAccesswire • 07/03/24
Probe Into Claims Against ARS Pharmaceuticals Inc Initiated By The Schall Law Firm And Impacted Investors Are Encouraged To ParticipateAccesswire • 07/02/24
The Schall Law Firm Initiates Probe Into Claims Against ARS Pharmaceuticals Inc And Urges Affected Investors To ParticipateAccesswire • 06/28/24
ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)GlobeNewsWire • 06/28/24
The Schall Law Firm Begins Investigation Into Allegations Against ARS Pharmaceuticals Inc And Encourages Impacted Investors To Get InvolvedAccesswire • 06/27/24
The Schall Law Firm Begins Investigation Into Allegations Against ARS Pharmaceuticals Inc And Encourages Impacted Investors To JoinAccesswire • 06/25/24
The Schall Law Firm Starts Investigation Into Allegations Against ARS Pharmaceuticals Inc And Encourages Impacted Investors To Get InvolvedAccesswire • 06/23/24
The Schall Law Firm Begins Probe Into Claims Against ARS Pharmaceuticals Inc And Urges Affected Investors To ParticipateAccesswire • 06/22/24
The Schall Law Firm Initiates Investigation Into Allegations Against ARS Pharmaceuticals Inc And Encourages Impacted Investors To Get InvolvedAccesswire • 06/21/24